Experienced in Pneumocystis Jiroveci Pneumonia

Peter E. Messiaen

't Hasselt, VLG, BE 
Experienced in Pneumocystis Jiroveci Pneumonia
't Hasselt, VLG, BE 
OverviewLocationsClinical Research

Overview

Peter Messiaen practices in 't Hasselt, Belgium. Mr. Messiaen is rated as an Experienced expert by MediFind in the treatment of Pneumocystis Jiroveci Pneumonia. His top areas of expertise are HIV/AIDS, Sepsis, COVID-19, Pneumocystis Jiroveci Pneumonia, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 32 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Pneumocystis Jiroveci Pneumonia.

Gender
Male

Locations

't Hasselt, VLG, Belgium
Other Locations
Diepenbeek, VLG, Belgium
Gent, VLG, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Drugs: Cabotegravir, Rilpivirine, BIKTARVY
Study Phase: Phase 3
Fast Assay for Pathogen Identification - Quasi-Experimental Intervention Study
Fast Assay for Pathogen Identification - Quasi-Experimental Intervention Study
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Diagnostic test
Study Phase: Not Applicable
Fast Assay for Pathogen Identification and Characterization - Prospective Observational Study
Fast Assay for Pathogen Identification and Characterization - Prospective Observational Study
Enrollment Status: Completed
Publish Date: April 29, 2020
View 2 Less Clinical Trials

32 Total Publications

Reply to Satapathy et al.'s comment on "Dual cross-sectional and longitudinal perspective on the continuum of HIV care to disentangle natural epidemic evolution from real progress, Belgium 2014-2022".
Reply to Satapathy et al.'s comment on "Dual cross-sectional and longitudinal perspective on the continuum of HIV care to disentangle natural epidemic evolution from real progress, Belgium 2014-2022".
Journal: HIV medicine
Published: November 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Messiaen's expertise for a condition
ConditionClose
      View All 7 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile